(function(){
			var content_array=["<p><b>关于捷帕力<\/b><b><sup>&reg;<\/sup><\/b><b>（匹妥布替尼）<\/b><\/p> \n<p>捷帕力<sup>&reg;<\/sup>（匹妥布替尼，又名&nbsp;LOXO-305）是一种高选择性（在临床前研究中，对 BTK 的选择性比98% 的其他激酶高 300 倍）、非共价（可逆）的BTK抑制剂<sup>[6]<\/sup>。BTK 是经过验证的分子靶标，在许多 B 细胞白血病和淋巴瘤（包括套细胞淋巴瘤）中被发现<sup>[7],[8]<\/sup>。<\/p> \n<p><b>关于套细胞淋巴瘤（<\/b><b>MCL）<\/b><\/p> \n<p>套细胞淋巴瘤（MCL） 是一种罕见的血液肿瘤，也是非霍奇金淋巴瘤 (NHL)的一种亚型。中国每年大约每50万人中有一人患上 MCL。MCL 源自于 B 淋巴细胞，是一种白细胞，也是免疫系统的一部分。 MCL 通常发生于淋巴结外缘套区的 B 细胞，随着肿瘤的进展，它会扩散到骨髓、脾脏、肝脏或消化道<sup>[9]<\/sup>。<\/p> \n<p><b>关于礼来制药<\/b><\/p> \n<p>礼来制药是一家致力于通过科学创新改善人类健康水平，惠及全球患者的医药公司。作为医疗健康行业的领军者，礼来制药拥有近150年的历史。今天，我们的药物已帮助全球数千万人。运用生物技术、化学和基因医学的力量，我们的科学家正在积极推动新的医学进展，以应对严峻的全球健康挑战。重新定义糖尿病与肥胖疗法，减少肥胖对人体的长期影响；助力阿尔茨海默病的防治行动；为一系列威胁人类健康的免疫性疾病提供解决方案；以及将难以治愈的癌症转变为可控的疾病。礼来制药迈向健康世界的每一步，都源自于我们&quot;致力于让数百万患者生活得更美好&quot;的信念。这包括致力于解决全球多重挑战的创新临床试验，同时确保药物的可及性和可负担性。如果需要了解更多关于礼来制药的信息，请登录：www.lilly.com。<\/p> \n<div> \n <table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\"> \n  <tbody> \n   <tr> \n    <td class=\"prnpr2 prnpl2 prnsbtb1 prnrbrb1 prnsbbb1 prnsblb1\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">[1] Nirav N. S, Wojciech J, Pier Z, et al. Pirtobrutinib in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Mantle Cell Lymphoma (MCL): Updated Results and Subgroup Analysis from the Phase 1\/2 BRUIN Study with 2 Years of Survival Follow-up. Journal of Clinical Oncology, Volume 41, Number 16_suppl. doi: 10.1200\/JCO.2023.41.16_suppl.7514<br \/>[2] Michael L. W, Nirav N. S, Wojciech J, et al. Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed \/ Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1\/2 BRUIN Study. Blood (2022) 140 (Supplement 1): 9368–9372. doi: 10.1182\/blood-2022-159425<br \/>[3] Yuqin S, Shuhua Y, Haiyan Y et al. Pirtobrutinib, a Non-Covalent (Reversible) BTK Inhibitor in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study. Blood, Volume 142, Supplement 1, 2 November 2023, Page 3636. Doi: 10.1182\/blood-2023-173287<br \/>[4] Georg H, Martin D Lucie O, Eva G, et al. Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. Br J Haematol. 2022 Oct 18;202(4):749–759. doi: 10.1111\/bjh.18519. doi: 10.1111\/bjh.18519<br \/>[5] Lisa M. H, Yongmei C, Paolo B. A, et al. Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real World Electronic Medical Records Study. Adv Hematol. 2022 Dec 28:2022:8262787. doi: 10.1155\/2022\/8262787.<br \/>[6] Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397(10277):892-901. doi:10.1016\/S0140-6736(21)00224-5<br \/>[7] Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79. Published 2020 Jun 17. doi:10.1186\/s13045-020-00914-1<br \/>[8] Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40. Published 2021 Mar 6. doi:10.1186\/s13045-021-01049-7<br \/>[9] National Organization for Rare Disorders. Mantle cell lymphoma. Accessed 26 October 2022. <a href=\"https:\/\/t.prnasia.com\/t\/FDArJBa0\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">https:\/\/rarediseases.org\/rare-diseases\/mantle-cell-lymphoma<\/a><\/span><\/p> <\/td> \n   <\/tr> \n  <\/tbody> \n <\/table> \n<\/div> \n<p>&nbsp;<\/p>"];
			$("#dvExtra").html(content_array[0]);})();